NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $435,306 | -50.0% | 406,828 | +20.9% | 0.00% | -50.0% |
| Q2 2023 | $871,364 | -37.6% | 336,434 | -1.6% | 0.00% | -50.0% |
| Q1 2023 | $1,395,450 | -0.4% | 342,022 | +22.5% | 0.00% | 0.0% |
| Q4 2022 | $1,401,534 | -58.8% | 279,190 | +7.4% | 0.00% | -66.7% |
| Q3 2022 | $3,400,000 | +57.0% | 259,940 | +53.9% | 0.01% | +71.4% |
| Q2 2022 | $2,166,000 | -3.5% | 168,920 | +14.8% | 0.01% | 0.0% |
| Q1 2022 | $2,245,000 | -46.4% | 147,198 | -37.8% | 0.01% | -22.2% |
| Q4 2021 | $4,191,000 | -4.3% | 236,659 | +13.6% | 0.01% | -10.0% |
| Q3 2021 | $4,379,000 | +1498.2% | 208,320 | +1398.7% | 0.01% | +900.0% |
| Q2 2021 | $274,000 | -86.2% | 13,900 | -79.6% | 0.00% | -80.0% |
| Q1 2021 | $1,981,000 | +151.4% | 68,147 | +37.6% | 0.01% | +66.7% |
| Q3 2020 | $788,000 | -18.3% | 49,542 | +1.5% | 0.00% | -40.0% |
| Q2 2020 | $964,000 | – | 48,815 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |